February 15, 2017Open Access

Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

In patients with rheumatoid arthritis who had had an inadequate response to methotrexate, baricitinib was associated with significant clinical improvements as compared with placebo and adalimumab. (Funded by Eli Lilly and Incyte; ClinicalTrials.gov number, NCT01710358 .).

Leer artículo completoexternamente

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo

Cite This Study

Taylor et al. (Wed,) studied this question.

synapsesocial.com/papers/69d8483f7392c8ce61beebab https://doi.org/https://doi.org/10.1056/nejmoa1608345

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales.1983 · 1,316 citations
2How to read radiographs according to the Sharp/van der Heijde method.1999 · 1,152 citations
3Assessment of radiographs in longitudinal observational studies.2004 · 17 citations
4American college of rheumatology preliminary definition of improvement in rheumatoid arthritis1995 · 2,844 citations
5Modified disease activity scores that include twenty-eight-joint counts development and validation in a prospective longitudinal study of patients with rheumatoid arthritis1995 · 6,226 citations

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo